Synopsis A recent clinical study shows that an adjuvant therapy with 200 mg of pembrolizumab in the patients with high-risk stage III melanoma resulted in significantly longer recurrence-free survival. The present study aims to evaluate the efficacy and safety of pembrolizumab as adjuvant therapy in the patients with resected, high-risk stage III melanoma. This week’s “ MED FACT ” discusses a clinical trial from The New England Journal of Medicine, “ Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma ”. April 2018. Authors : Alexander M.M. Eggermont; Christian U.
Blank; Mario Mandala; et. al. Key Takeaways: Pembrolizumab therapy lowers the risk of recurrence-free survival by 43%. It also decreases the number of patients with PD-L1 positive tumors by 46%. Objective: To evaluate the efficacy and safety of pembrolizumab in the patients with resected, high-risk stage III…
